State of the Art: Blood Biomarkers for Risk Stratification in Patients with Stable Ischemic Heart Disease.

No abstract is available for this paper.

• Publication year

  2017

• Venue

  Clinical Chemistry

• Publication date

  Unknown publication date

• Fields of study

  Medicine

• Identifiers
  DOI 10.1373/clinchem.2016.255190PMID 27815307
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• High-sensitivity Troponin T in relation to coronary plaque characteristics in patients with stable coronary artery disease; results of the ATHEROREMO-IVUS study.

  2016cited by this paper
• Growth Differentiation Factor 15, Its 12-Month Relative Change, and Risk of Cardiovascular Events and Total Mortality in Patients with Stable Coronary Heart Disease: 10-Year Follow-up of the KAROLA Study.

  2016cited by this paper
• Development and Validation of a Protein-Based Risk Score for Cardiovascular Outcomes Among Patients With Stable Coronary Heart Disease.

  2016cited by this paper
• Circulating microRNAs strongly predict cardiovascular death in patients with coronary artery disease—results from the large AtheroGene study

  2016cited by this paper
• Traditional Risk Factors Versus Biomarkers for Prediction of Secondary Events in Patients With Stable Coronary Heart Disease: From the Heart and Soul Study

  2015cited by this paper
• Inflammation and plaque vulnerability

  2015cited by this paper
• miRNA-197 and miRNA-223 Predict Cardiovascular Death in a Cohort of Patients with Symptomatic Coronary Artery Disease

  2015cited by this paper
• Relationship Between Subclinical Cardiac Troponin I Elevation and Culprit Lesion Characteristics Assessed by Optical Coherence Tomography in Patients Undergoing Elective Percutaneous Coronary Intervention

  2015cited by this paper
• Biomarkers in stable coronary heart disease, their modulation and cardiovascular risk: The LIPID biomarker study.

  2015cited by this paper
• Troponin and Cardiac Events in Stable Ischemic Heart Disease and Diabetes.

  2015cited by this paper
• Elevated small dense low-density lipoprotein cholesterol as a predictor for future cardiovascular events in patients with stable coronary artery disease.

  2014cited by this paper
• Prediction of Cardiovascular Events in Statin-Treated Stable Coronary Patients of the Treating to New Targets Randomized Controlled Trial by Lipid and Non-Lipid Biomarkers

  2014cited by this paper
• Review of Cardiovascular Literature

  2014cited by this paper
• Darapladib for preventing ischemic events in stable coronary heart disease.

  2014cited by this paper
• Relation of C-reactive protein to coronary plaque characteristics on grayscale, radiofrequency intravascular ultrasound, and cardiovascular outcome in patients with acute coronary syndrome or stable angina pectoris (from the ATHEROREMO-IVUS study).

  2014cited by this paper
• Fibroblast growth factor-23, cardiovascular prognosis, and benefit of angiotensin-converting enzyme inhibition in stable ischemic heart disease.

  2014cited by this paper
• Comparative prognostic value of low-density lipoprotein cholesterol and C-reactive protein in patients with stable coronary artery disease treated with percutaneous coronary intervention and chronic statin therapy.

  2014cited by this paper
• Association of contemporary sensitive troponin I levels at baseline and change at 1 year with long-term coronary events following myocardial infarction or unstable angina: results from the LIPID Study (Long-Term Intervention With Pravastatin in Ischaemic Disease).

  2014cited by this paper
• Growth differentiation factor 15 and cardiovascular events in patients with stable ischemic heart disease (The Heart and Soul Study).

  2014cited by this paper
• Biomarkers of chronic cardiac injury and hemodynamic stress identify a malignant phenotype of left ventricular hypertrophy in the general population.

  2013cited by this paper
• Changes in Lipoprotein‐Associated Phospholipase A2 Activity Predict Coronary Events and Partly Account for the Treatment Effect of Pravastatin: Results From the Long‐term Intervention with Pravastatin in Ischemic Disease Study

  2013cited by this paper
• The third universal definition of myocardial infarction

  2013cited by this paper
• Diagnostic Potential of Plasmatic MicroRNA Signatures in Stable and Unstable Angina

  2013cited by this paper
• Prognostic value of cardiac troponin I measured with a highly sensitive assay in patients with stable coronary artery disease.

  2013cited by this paper
• ESC guidelines on the management of stable coronary artery disease — addenda The Task Force on the management of stable coronary artery disease of the European Society of Cardiology

  2013cited by this paper
• Clinical implications of the Third Universal Definition of Myocardial Infarction

  2013cited by this paper
• 2013 ESC guidelines on the management of stable coronary artery disease: the Task Force on the management of stable coronary artery disease of the European Society of Cardiology.

  2013cited by this paper
• Biomarkers in acute coronary syndromes

  2012cited by this paper
• Determination of 19 cardiac troponin I and T assay 99th percentile values from a common presumably healthy population.

  2012cited by this paper
• Third universal definition of myocardial infarction.

  2012cited by this paper
• Troponin I measured by a high-sensitivity assay in patients with suspected reversible myocardial ischemia: data from the Akershus Cardiac Examination (ACE) 1 study.

  2012cited by this paper
• Evaluation of Multiple Biomarkers of Cardiovascular Stress for Risk Prediction and Guiding Medical Therapy in Patients With Stable Coronary Disease

  2012cited by this paper
• Analytical characteristics of high-sensitivity cardiac troponin assays.

  2012cited by this paper
• Women and men with stable coronary artery disease have similar clinical outcomes: insights from the international prospective CLARIFY registry

  2012cited by this paper
• Advances in Acute Coronary Syndrome Management

  2012cited by this paper
• Extensions of net reclassification improvement calculations to measure usefulness of new biomarkers

  2011cited by this paper
• Pathobiology of troponin elevations: do elevations occur with myocardial ischemia as well as necrosis?

  2011cited by this paper
• Prognostic utility of secretory phospholipase A(2) in patients with stable coronary artery disease.

  2011cited by this paper
• Myocardial ischemia induced by rapid atrial pacing causes troponin T release detectable by a highly sensitive assay: insights from a coronary sinus sampling study.

  2011cited by this paper
• Plasma myeloperoxidase predicts incident cardiovascular risks in stable patients undergoing medical management for coronary artery disease.

  2011cited by this paper
• High-sensitivity troponin T level and angiographic severity of coronary artery disease.

  2011cited by this paper
• Multiple marker approach to risk stratification in patients with stable coronary artery disease.

  2010cited by this paper
• Evaluating the Quality of Research into a Single Prognostic Biomarker: A Systematic Review and Meta-analysis of 83 Studies of C-Reactive Protein in Stable Coronary Artery Disease

  2010cited by this paper
• New features of troponin testing in different clinical settings

  2010cited by this paper
• Screening the population for left ventricular hypertrophy and left ventricular systolic dysfunction using natriuretic peptides: results from the Dallas Heart Study.

  2009cited by this paper
• Criteria for Evaluation of Novel Markers of Cardiovascular Risk: A Scientific Statement From the American Heart Association

  2009cited by this paper
• Inflammation and Plaque Vulnerability

  2009cited by this paper
• Growth-Differentiation Factor-15 for Risk Stratification in Patients With Stable and Unstable Coronary Heart Disease: Results From the AtheroGene Study

  2009cited by this paper
• Genetically elevated C-reactive protein and ischemic vascular disease

  2009cited by this paper
• A sensitive cardiac troponin T assay in stable coronary artery disease.

  2009cited by this paper
• Genetically elevated C-reactive protein and ischemic vascular disease.

  2008cited by this paper
• Detection of acute changes in circulating troponin in the setting of transient stress test-induced myocardial ischaemia using an ultrasensitive assay: results from TIMI 35.

  2008cited by this paper
• Prognostic value of B-Type natriuretic peptides in patients with stable coronary artery disease: the PEACE Trial.

  2007cited by this paper
• Benchmarks for the Assessment of Novel Cardiovascular Biomarkers

  2007cited by this paper
• N-terminal fragment of the prohormone brain-type natriuretic peptide (NT-proBNP), cardiovascular events, and mortality in patients with stable coronary heart disease.

  2007cited by this paper
• Prognostic Significance of the Centers for Disease Control/American Heart Association High-Sensitivity C-Reactive Protein Cut Points for Cardiovascular and Other Outcomes in Patients With Stable Coronary Artery Disease

  2007cited by this paper
• Biomarkers of Cardiovascular Disease: Molecular Basis and Practical Considerations

  2006cited by this paper
• Is N-terminal pro B-type natriuretic peptide (NT-proBNP) a useful screening test for angiographic findings in patients with stable coronary disease?

  2006cited by this paper
• Prognostic value of circulating pregnancy-associated plasma protein levels in patients with chronic stable angina.

  2006cited by this paper
• Comparative Impact of Multiple Biomarkers and N-Terminal Pro-Brain Natriuretic Peptide in the Context of Conventional Risk Factors for the Prediction of Recurrent Cardiovascular Events in the Heart Outcomes Prevention Evaluation (HOPE) Study

  2006cited by this paper
• Predicting prognosis in stable angina—results from the Euro heart survey of stable angina: prospective observational study

  2006cited by this paper
• Interleukin-6 and the risk of future cardiovascular events in patients with angina pectoris and/or healed myocardial infarction.

  2006cited by this paper
• Renal Function and Effectiveness of Angiotensin-Converting Enzyme Inhibitor Therapy in Patients With Chronic Stable Coronary Disease in the Prevention of Events with ACE inhibition (PEACE) Trial

  2006cited by this paper
• Prevalence and Determinants of Troponin T Elevation in the General Population

  2006cited by this paper
• B-type natriuretic peptide and long-term survival in patients with stable coronary artery disease.

  2005cited by this paper
• White Blood Cell Count Predicts Reduction in Coronary Heart Disease Mortality With Pravastatin

  2005cited by this paper
• N-terminal pro-B-type natriuretic peptide and long-term mortality in stable coronary heart disease.

  2005cited by this paper
• C-reactive protein levels and outcomes after statin therapy.

  2005cited by this paper
• Overall C as a measure of discrimination in survival analysis: model specific population value and confidence interval estimation

  2004cited by this paper
• Acute changes in circulating natriuretic peptide levels in relation to myocardial ischemia.

  2004cited by this paper
• Angiotensin-converting-enzyme inhibition in stable coronary artery disease.

  2004cited by this paper
• N-Terminal Pro-B-Type Natriuretic Peptide and Long-Term Mortality in Acute Coronary Syndromes

  2002cited by this paper
• Ability of minor elevations of troponins I and T to predict benefit from an early invasive strategy in patients with unstable angina and non-ST elevation myocardial infarction: results from a randomized trial.

  2001cited by this paper
• The prognostic value of B-type natriuretic peptide in patients with acute coronary syndromes.

  2001cited by this paper
• Preprocedural serum levels of C-reactive protein predict early complications and late restenosis after coronary angioplasty.

  1999cited by this paper
• Elevated serum intercellular adhesion molecule-1 and vascular adhesion molecule-1 among patients with stable angina pectoris who suffer cardiovascular death or non-fatal myocardial infarction.

  1999cited by this paper
• Plasma brain natriuretic peptide as an indicator of left ventricular systolic function and long-term survival after acute myocardial infarction. Comparison with plasma atrial natriuretic peptide and N-terminal proatrial natriuretic peptide.

  1996cited by this paper
• Increased plasma levels of B-type natriuretic peptide in patients with unstable angina.

  1996cited by this paper

• CABIT: a novel biomarkers-integrated inflammatory risk tool for ischemic heart disease developed in the USA and prospectively validated in China

  2026influential citation
• Correlation of Mean Platelet Volume With Angiographic Severity in Diabetic Coronary Artery Disease: A Cross-Sectional Study.

  2026cites this paper
• Association of fibrinogen-to-albumin ratio with all-cause and cardiovascular mortality in patients on dialysis with acute coronary syndrome.

  2025cites this paper
• Biomarkers in coronary artery disease: systematic review and meta-analysis.

  2025cites this paper
• Reproducible biomarkers: Leveraging nonlinear descriptors in the face of non-ergodicity

  2023cites this paper
• Multifractal foundations of biomarker discovery for heart disease and stroke

  2023cites this paper
• Biomarkers of non-communicable chronic disease: an update on contemporary methods

  2022cites this paper
• Differences between high-sensitivity cardiac troponin T and I in stable populations: underlying causes and clinical implications

  2022cites this paper
• Association of GDF-15, hs-cTnT and NT-proBNP with coronary artery disease in patients undergoing elective angiography.

  2022cites this paper
• High fibrinogen-to-albumin ratio with type 2 diabetes mellitus is associated with poor prognosis in patients undergoing percutaneous coronary intervention: 5-year findings from a large cohort

  2022cites this paper
• Plasma proteins associated with cardiovascular death in patients with chronic coronary heart disease: A retrospective study

  2021cites this paper
• Diagnosis and Management of Stable Angina: A Review.

  2021cites this paper
• Association between vitamin D deficiency and serum Homocysteine levels and its relationship with coronary artery disease

  2021cites this paper
• Personalised Approach to Atherosclerotic Cardiovascular Disease: The Future is Here

  2021cites this paper
• Antioxidant/Pro-Oxidant Actions of Polyphenols From Grapevine and Wine By-Products-Base for Complementary Therapy in Ischemic Heart Diseases

  2021cites this paper
• Circulating Biomarkers for Cardiovascular Disease Risk Prediction in Patients With Cardiovascular Disease

  2021cites this paper
• Elevated serum lipoprotein(a) is significantly associated with angiographic progression of coronary artery disease

  2021cites this paper
• Prognostic utility of lipoprotein(a) combined with fibrinogen in patients with stable coronary artery disease: a prospective, large cohort study

  2020cites this paper
• Using High-Sensitivity Cardiac Troponin for the Exclusion of Inducible Myocardial Ischemia in Symptomatic Patients

  2020cites this paper
• Total Microfluidic chip for Multiplexed diagnostics (ToMMx).

  2020cites this paper
• Systemic Cardiac Troponin T Associated With Incident Atrial Fibrillation Among Patients With Suspected Stable Angina Pectoris.

  2020cites this paper
• Imaging tools for assessment of myocardial fibrosis in humans: the need for greater detail

  2020cites this paper
• Advances in Cardiovascular Biomarker Discovery

  2020cites this paper
• Non-invasive Risk Stratification for Coronary Artery Disease: Is It Time for Subclassifications?

  2019cites this paper
• Cardiac Troponin Elevation in Patients Without a Specific Diagnosis.

  2019cites this paper
• Recommendations for Institutions Transitioning to High-Sensitivity Troponin Testing: JACC Scientific Expert Panel.

  2019cites this paper
• Acupuncture to Improve Symptoms for Stable Angina: Protocol for a Randomized Controlled Trial

  2019cites this paper
• Acupuncture to Improve Symptoms for Stable Angina (AIMS-A): Study Protocol for a Randomized Controlled Trial (Preprint)

  2019cites this paper
• Cardiac Troponin T Concentrations, Reversible Myocardial Ischemia, and Indices of Left Ventricular Remodeling in Patients with Suspected Stable Angina Pectoris: a DOPPLER-CIP Substudy.

  2018cites this paper
• Growth differentiation factor 15 in cardiovascular diseases: Are we needed novel biomarker?

  2018cites this paper
• OBSOLETE: Biomarkers in Ischemic Heart Disease

  2018cites this paper
• Promising utilities of growth differentiation factor 15 in cardiovascular diseases

  2018cites this paper
• Prospective Validation of a Biomarker-Based Rule Out Strategy for Functionally Relevant Coronary Artery Disease.

  2018cites this paper
• Can C-reactive Protein Genetic Variants Identify Patients with Higher and Lower Cardiovascular Risk?

  2018cites this paper
• The Single Nucleotide Polymorphisms in the C-reactive Protein Gene: are they Biomarkers of Cardiovascular Risk?

  2018cites this paper
• Age-Biomarkers-Clinical Risk Factors for Prediction of Cardiovascular Events in Patients With Coronary Artery Disease

  2018cites this paper
• Growth differentiation factor‐15 is not modified by sacubitril/valsartan and is an independent marker of risk in patients with heart failure and reduced ejection fraction: the PARADIGM‐HF trial

  2018cites this paper
• Usefulness of Higher Levels of Cardiac Troponin T in Patients With Stable Angina Pectoris to Predict Risk of Acute Myocardial Infarction.

  2018cites this paper
• Biomarkers in Ischemic Heart Disease

  2017cites this paper